Bone mineral density and spongiosa architecture in correlation to vertebral body insufficiency fractures

1998 ◽  
Vol 39 (5) ◽  
pp. 538-542 ◽  
Author(s):  
R. Andresen ◽  
S. Radmer ◽  
D. Banzer
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Vertebral Body ◽  
Unknown Etiology ◽  
Insufficiency Fractures ◽  
Mineral Density ◽  
Group Iii ◽  
Group I ◽  
The Mean ◽  
Group Ii

Objective: the clinical value of spinal quantitative CT (sQCT) and the structural patterns of the vertebral bone were studied Material and Methods: sQCT was performed on 246 patients with a mean age of 57 years for whom conventional lateral radiographies of the thoracic and lumbar spine were available. All patients were suffering from back pain of unknown etiology. the bone mineral density (BMD) of the midvertebral section of 3 lumbar vertebral bodies was determined by means of single-energy-(SE)-weighted QCT (85 kV). Spongiosa architecture and density profile analyses were made in the axial images. This was contrasted to BMD values ascertained in SE QCT. the mean BMD was compared to the number of fractures and the patients were divided into three groups: group I — no fracture; group II — one fracture; and group III 1 fracture Results: the mean BMD was: 134.3 (74.1–187.5) mg hydroxyapatite (HA)/ml in group I; 79.6 (58.6–114.3) mg HA/ml in group II; and 52.4 (13.1–79.1)mg HA/ml in group III. A significant deterioration in spongiosa structure was found with increasing demineralization: strongly rarefied patterns predominated in the fracture groups II and III Conclusion: sQCT provides a good risk assessment of the occurrence of vertebral body insufficiency fractures

scholarly journals CELIAC DISEASE;

2018 ◽  
Vol 21 (02) ◽  
pp. 275-279
Author(s):  
Sikandar Ali Bhand ◽  
Farzana Shaikh ◽  
Hussain Bux Korejo ◽  
Syed Jamal Raza
Keyword(s):  
Bone Mineral Density ◽  
Celiac Disease ◽  
Bone Mineral ◽  
Gluten Free Diet ◽  
P Value ◽  
Gluten Free ◽  
Mineral Density ◽  
Dexa Scan ◽  
Group I ◽  
Group Ii

Objective: To evaluate effectiveness of treating previously untreated patients withceliac disease with both a gluten free diet and bisphosphonate in order to significantly increasetheir BMD’s to a greater extent than a gluten free diet alone. Patients and methods: The studywas conducted in National Institute of Child Health (NICH) Karachi to evaluate the effectiveness oftreating previously untreated patients with celiac disease with a gluten free diet andbisphosphonate in terms of increase in bone mineral density in comparison to a gluten free dietalone over a period of three months (January 2013 – March 2013). The study includes 30 childrenpatients below fifteen years of age either sex. All study subjects were untreated celiac patientsdiagnosed by clinical presentation, small bowel histology and serologic testing. On day dexascan was done. Fifteen patients kept on Gluten Free Diet (GFD) and remaining 15 patients keptGFD plus tablet of bisphosphonate. After three months dexa scan was repeated. The patientswith other disease of bone or mineral metabolism, as well as subjects taking systemicglucocorticoids or high doses of thyroid hormones, were excluded. Results: A total of 30 patientswith celiac disease were included in this study. Out of 30 patients 18 (60%) were female and 12(40%) male (M: F = 1:1.5). Thirty patients were divided in two equal groups (15 patients in eachgroup). In group-I we gave gluten free diet and in group-II we gave gluten free diet and one tabletof bisphosphonate. Mean± SD of Bone Mineral Density (BMD) in group-I was 0.402± 0.081gm/cm2 (range=0.234 – 0.503 gm/cm2), and in group-II was 0.543± 0.098 gm/cm2 (range=0.402 – 0.743 gm/cm2), mean difference of bone mineral density was significant between twogroups (P-value=0.0002). Conclusions: At three months DEXA scan showed a significant rise inBMD in group-II as compared to group-I

Increased Bone Mineral Density Adjacent to Hydroxy-Apatite-Coated Ankle Arthroplasty

2000 ◽  
Vol 21 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Bo Zerahn ◽  
Hakon Kofoed ◽  
Arne Borgwardt
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Distal Tibia ◽  
Mineral Density ◽  
Hydroxy Apatite ◽  
Ankle Arthroplasty ◽  
Group I ◽  
Fixed Prosthesis ◽  
Group Ii

We measured bone mineral density (BMD) in patients treated with a unilateral hydroxy-apatite-coated ankle arthroplasty. The study comprised 11 consecutive patients measured preoperatively and postoperatively after 3, 6, and 12 months (group I) and 17 patients measured once at 12 to 82 months follow-up (group II). BMD was measured in the distal tibia adjacent to the prosthesis and in the calcaneus. BMD of the calcaneus was measured bilaterally as an indicator of changes in foot load. In group I BMD was significantly increased in the distal tibia after 6 and 12 months compared to preoperative values. In group II BMD of the distal tibia was significantly higher compared to the non-operated side. No radiolucencies were detected during follow-up in any case. The increase in BMD and the radiogaphic findings after uncemented ankle arthroplasty indicates that it is being loaded by the prosthesis. This may indicate a well fixed prosthesis.

Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy

2019 ◽  
Vol 15 (5) ◽  
pp. 395-401 ◽  
Author(s):  
Hussein A. El Oraby ◽  
Mona M. Abdelsalam ◽  
Yara M. Eid ◽  
Rana El Hilaly ◽  
Heba A. Marzouk
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Female Gender ◽  
Charcot Arthropathy ◽  
Mineral Density ◽  
T Score ◽  
Group I ◽  
Group Ii ◽  
Risk Predictors

Introduction: Charcot arthropathy is one of the disabling diabetes complications. There are enigmatic areas concerning its underlying pathophysiology and risk predictors. Osteoporosis and local osteopenia have been postulated to have a role in Charcot arthropathy development, but it is still controversial. Background: The study aims to compare bone mineral density among type 2 diabetics with and without Charcot arthropathy. Methods: Two groups with type 2 diabetes participated in this study; Group I [30] patients with Charcot arthropathy while Group II [30] patients without charcot arthropathy. All patients underwent full clinical examination and complete history taking with special emphasis on foot problems. Laboratory investigations were done that included fasting blood sugar, postprandial blood sugar, glycosylated hemoglobin, serum calcium, serum phosphorus, and alkaline phosphatase. All patients underwent MRI for both feet and dual energy X-ray absorptiometry scan of the lumbar spine and femur. The demographic data, clinical data, the presence or absence of comorbidities and bone mineral density were compared for both groups. Results: Bone mineral density was significantly lower in Group I than Group II with median lumber T score (-0.15, 1.99 p <0.001), median Femur T score (0.050, 2.400, p <0.001). Group I showed higher propensity for hypertension, neuropathy, micro-albuminuria with peripheral arterial disease (23.33 %) compared to Group II (p <0.001). Multiple logistic regression analysis revealed that female gender and low femur bone mineral density can be risk predictors of the condition. Conclusion: Bone mineral density is lower in patients with Charcot arthropathy with female gender and Femur T score as risk predictors. Peripheral arterial disease shows greater incidence in Charcot patients than was previously reported.

CORRELATION OF SERUM CHOLESTEROL AND BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN

2021 ◽  
Vol 5 (12) ◽  
Author(s):  
Sawai Singh ◽  
Lokesh Soni
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Cholesterol Level ◽  
Bone Mineral ◽  
Serum Cholesterol ◽  
Mineral Density ◽  
Menopausal Women ◽  
The Mean ◽  
Group Ii ◽  
Post Menopausal

Background: To find a correlation between serum cholesterol and Bone mineral density in post menopausal women Methods: The study was carried on matched cases and controls. The experimental group consisted of 100 females at postmenopausal age, in which by the DEXA method was diagnosed osteoporosis while the control group consisted of 50 females in a postmenopausal age but without diagnosed osteoporosis who served as controls. Results: Postmenopausal women in the BMI range 18.5 to 25 (normal)were only included in the study. Others were excluded from the study to avoid confounding factors. The mean BMI in women with osteoporosis was 22.13±1.76 and in Group-II was 21.26±2.06. The results were statistically insignificant. Analyzing the average values of serum cholesterol in our study,we found that the mean cholesterol level in group-I was 210.32 ±34.21 mg/dl and 183.21 ±56.32 mg/dl in group-II. The mean cholesterol level was significantly higher in women with osteoporosis. Conclusion: On the decrease in bone mineral density and osteoporosis in postmenopausal women influence many risk factors. Preventive strategies for development of osteoporosis should be initiated in women with elevated serum cholesterol levels. Keywords: Osteoporosis, Menopause, Lipid Profile, BMI.

scholarly journals The Impact of Seropositivity on Bone Mineral Density in Rheumatoid Arthritis - A 3-year Prospective Observational Study

2021 ◽  
Author(s):  
Shan-Fu Yu ◽  
Jia-Feng Chen ◽  
Ying-Chou Chen ◽  
Yu-Wei Wang ◽  
Chung-Yuan Hsu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Loss ◽  
Bone Mineral ◽  
Mineral Density ◽  
Group Iii ◽  
Group I ◽  
Group A ◽  
Group B ◽  
The Impact

Abstract Background:To explore the impact of seropositivity on systemic bone loss in rheumatoid arthritis (RA).Methods:This was an interim analysis of the RA registry. Clinical characteristics in the registry were documented, and bone mineral density (BMD) was measured; this was repeated 3 years later. Participants were grouped into seropositive (SPRA) and seronegative (SNRA) based on the presence or absence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (ACPA). After matching (1:2) for age and sex, SNRA and SPRA were regrouped into A and B. To elucidate the impact of number of antibodies on BMD changes, the matched group was sub-divided according to the number of antibodies present (0, group I; 1, group II; 2, group III). The changes in BMD were compared for each group at baseline and 3 years later. Results:A total of 477 participants who completed a 3-year observation period were included. After matching, 312 participants were enrolled (group A, 104; group B, 208). Three years later, group B had significant bone loss in the femoral neck (FN) (p <0.001), total hip (TH) (p = 0.001), and 1st–4th lumbar vertebrae (L1–4) (p = 0.006), while group A has bone loss only at FN (p = 0.002). Groups I, II, and III included 104, 52, and 156 participants, respectively. Significant bone loss was recorded at FN (p = 0.002) in group I, FN (p <0.001) in group II, and FN (p <0.001), TH (p = 0.002), and L1–4 (p = 0.016) in group III. In terms of percent change in BMD (△BMD%), more significantly negative changes were found at TH in group B (p = 0.027) and within groups I-III (p for trend = 0.021). Logistic regression showed that seropositivity is a significant predictor of △BMD≧–5% at TH (odds ratio 1.85, 95% confidence interval 1.03-3.33, p = 0.039).Conclusions:SPRA lost more bone than SNRA after 3 years. More attention should be paid to SPRA patients, especially those with double-positive antibodies, with vigorous evaluation of BMD and fracture risk.

scholarly journals Comparative assessment of bone mineral density in recipients with preserved function and calcium degeneration of heart valve bioprotheses

2018 ◽  
pp. 83-88
Author(s):  
N. V. Rutkovskaya ◽  
A. N. Stasev ◽  
N. V. Kondyukova ◽  
O. K. Kuzmina ◽  
V. B. Fanaskov ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Heart Valve ◽  
Bone Mineral ◽  
Soft Tissues ◽  
Light And Electron Microscopy ◽  
Mineral Density ◽  
Mean Values ◽  
Group I ◽  
Group Ii ◽  
Microscopy Data

Aim. To study a bone mineral density (BMD) in recipients with calcium degeneration and preserved morphofunctional state of heart valve bioprotheses (BP).Material and methods. The experimental groups included the patients with structural dysfunctions of BP associated with the calcification of the xenomaterial, confirmed by light and electron microscopy data (group I, n=22) and the patients with normal functional state of the implanted valves according to the results of echocardiographic tests (group II, n=48). BMD was assessed by dual energy absorptiometry in the absolute count of mineralized bone and indicators of T­test.Results. When interpreting the T­test of a femoral neck the severity of osteopenic syndrome prevailed in patients with calcium degeneration of BP (­1,83 [­2,66; ­1,25] in group I vs ­1,47 [­2,51; ­0,86] in group II, р=0,055). At that the mean values of this indicator in patients with the development of calcium­associated BP dysfunctions in the first four years after a surgical correction of the defects reached the diagnostic criteria of the osteoporosis (­2,73 [­3,40; ­2,09] vs ­1,67 [­2,92; ­0,42], р>0,05). According to the result of absorptiometry of the lumbar spine the worst Т­score indicators were also recorded in recipients with the calcification of BP within the first four years of follow­up (­1,75 [­1,83; ­1,43] vs ­0,81 [­0,96; ­0,66] in patients without the signs of calcification, р=0,021). The state of BMD reflects the physiological and pathological processes of calcium redistribution in organism. The existence of the pathogenetic parallels between the activity of bone resorption processes and calcification of the elements of cardiovascular system allows to consider the osteopenia and pathological mineralization of the soft tissues within the framework of a single continuum. The results of the presented work in their turn testify to the determining significance of the severity of osteopenic syndrome manifestations in the development of the “early” calcium degeneration of BP.Conclusion. Extension of the concepts of the mechanisms and processes which form the pathogenetic basis of mineralization will allow to determine the effective strategies for managing the risk of calcium­associated BP dysfunctions.

scholarly journals Supplementation with bio-calcium from shells Pinctada maxima in postmenopausal women with decreased mineral bone density: Pilot study

2009 ◽  
Vol 137 (9-10) ◽  
pp. 518-523 ◽  
Author(s):  
Nada Vujasinovic-Stupar ◽  
Snezana Novkovic ◽  
Ivana Jezdic
Keyword(s):  
Bone Mineral Density ◽  
Pilot Study ◽  
Adverse Events ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Mineral Density ◽  
Biological Origin ◽  
Group I ◽  
Group Ii ◽  
Pinctada Maxima

Introduction Treatment of osteoporosis, in addition to a specific antiresorptive or anabolic treatment, requires supplementation with calcium and vitamin D. Widespread cultivation of pearl shells has made pearls available for commercial use for a very reasonable price. The main chemical compound of pearls from shells Pinctada maxima is calcium-carbonate (CaCO3). Recently developed technologies applied in a micronisation process have provided increased gastrointestinal resorption of calcium, estimated at over 90% of calcium intake. Objective The paper is aimed at monitoring of efficacy and tolerance of six-month bio-calcium supplementation in postmenopausal women with reduced bone mineral density. Methods Group I (30 patients) received, three times a day, capsules of pearl powder from shells Pinctada maxima (it is equal to 260 mg of elementary calcium); group II (20 patients) received a daily dose of 500 mg inorganic CaCO3. Both groups received 666 IU of cholecalciferol per day. In all patients, bone mineral density (BMD) of the spine or hip, serum blood and urine levels of Ca, phosphates and alkaline phosphatase, were measured before and after six months of the treatment. Results Group I/Group II: average age 61.7/61.7 years; beginning of menopause: 48.32 /48 years; menopause duration 13.4/13.7 years; average body mass index 27.2/27 kg/m2 . These two groups did not different significantly before supplementation. Six-month supplementation with CaCO3 of the biological origin led to the increase of BMD from 0.901 g/cm2 to 0.948 g/cm2 (p=0.067), while BMD remained the same in the group supplemented with inorganic CaCO3. Gastrointestinal tolerability of bio-calcium was excellent, without any adverse events. Conclusion These data could not strongly support the hypothesis of better efficacy of bio-calcium taking into account a small number of patients and a short follow-up period in this pilot study. Tolerance of CaCO3 of the biological origin was excellent and free of any adverse events. The results of laboratory values were within normal range.

scholarly journals SAT0462 ASSESSMENT OF BONE MINERAL DENSITY IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1188.1-1188
Author(s):  
C. Daldoul ◽  
N. El Amri ◽  
K. Baccouche ◽  
H. Zeglaoui ◽  
E. Bouajina
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Mineral Density ◽  
Femoral Site ◽  
Significant Difference ◽  
History Of ◽  
Inflammatory Bowel ◽  
The Mean

Background:Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is considered as a risk factor of low bone mineral density (BMD). In fact, the prevalence of osteoporosis ranges from 17% to 41% in IBD patients. The possible contributing factors may include malabsorption, glucocorticoid treatment and coexisting comorbiditiesObjectives:The purpose of our work was to determine the frequency and the determinants of osteoporosis in patients with IBD and to assess whether there is a difference in BMD status between UC and CD.Methods:This is a retrospective study, over a period of 5 years (from January 2014 to December 2018) and including patients followed for IBD who had a measurement of BMD by DEXA. Clinical, anthropometric and densitometric data (BMD at the femoral and vertebral site) were recorded. The WHO criteria for the definition of osteoporosis and osteopenia were applied.Results:One hundred and five patients were collected; among them 45 were men and 60 were women. The average age was 45.89 years old. The average body mass index (BMI) was 25.81 kg/m2 [16.44-44.15]. CD and UC were diagnosed in respectively 57.1% and 42.9%. A personal history of fragility fracture was noted in 4.8%. Hypothyroidism was associated in one case. Early menopause was recorded in 7.6%. 46.8% patients were treated with corticosteroids. The mean BMD at the vertebral site was 1.023 g/cm3 [0.569-1.489 g/cm3]. Mean BMD at the femoral site was 0.920g/cm3 [0.553-1.286g / cm3]. The mean T-score at the femoral site and the vertebral site were -1.04 SD and -1.27 SD, respectively. Osteoporosis was found in 25.7% and osteopenia in 37.1%. Osteoporosis among CD and UC patients was found in respectively 63% and 37%. The age of the osteoporotic patients was significantly higher compared to those who were not osteoporotic (52.23 vs 43.67 years, p = 0.01). We found a significantly higher percentage of osteoporosis among men compared to women (35.6% vs 18.3%, p=0.046). The BMI was significantly lower in the osteoporotic patients (23.87 vs 26.48 kg/m2, p=0.035) and we found a significant correlation between BMI and BMD at the femoral site (p=0.01). No increase in the frequency of osteoporosis was noted in patients treated with corticosteroids (27.9% vs 21.6%, p=0.479). Comparing the UC and CD patients, no difference was found in baseline characteristics, use of steroids or history of fracture. No statistically significant difference was found between UC and CD patients for osteoporosis(p=0.478), BMD at the femoral site (p=0.529) and at the vertebral site (p=0.568).Conclusion:Osteoporosis was found in 25.7% of IBD patients without any difference between CD and UC. This decline does not seem to be related to the treatment with corticosteroids but rather to the disease itself. Hence the interest of an early screening of this silent disease.Disclosure of Interests:None declared

Anterior bone cement augmentation in anterior lumbar interbody fusion and percutaneous pedicle screw fixation in patients with osteoporosis

2010 ◽  
Vol 12 (5) ◽  
pp. 525-532 ◽  
Author(s):  
Kyeong Hwan Kim ◽  
Sang-Ho Lee ◽  
Dong Yeob Lee ◽  
Chan Shik Shim ◽  
Dae Hyeon Maeng
Keyword(s):  
Vertebral Body ◽  
Interbody Fusion ◽  
Anterior Lumbar Interbody Fusion ◽  
Cement Augmentation ◽  
Adjacent Segment ◽  
Lumbar Interbody Fusion ◽  
Group I ◽  
Cage Subsidence ◽  
The Mean ◽  
Group Ii

Object The purpose of the present study was to evaluate the efficacy of anterior polymethylmethacrylate (PMMA) cement augmentation in instrumented anterior lumbar interbody fusion (ALIF) for patients with osteoporosis. Methods Sixty-two patients with osteoporosis who had undergone single-level instrumented ALIF for spondylolisthesis and were followed for more than 2 years were included in the study. The patients were divided into 2 groups: instrumented ALIF alone (Group I) and instrumented ALIF with anterior PMMA augmentation (Group II). Sixty-one patients were interviewed to evaluate the clinical results, and plain radiographs and 3D CT scans were obtained at the last follow-up in 46 patients. Results The mean degree of cage subsidence was significantly higher in Group I (19.6%) than in Group II (5.2%) (p = 0.001). The mean decrease of vertebral body height at the index level was also significantly higher in Group I (10.7%) than in Group II (3.9%) (p = 0.001). No significant intergroup differences were observed in the incidence of radiographic adjacent-segment degeneration (ASD) or in terms of pain and functional improvement. The incidences of clinical ASD (23% in Group I and 10% in Group II) were not significantly different. There was 1 case of nonunion and 3 cases of screw migration in Group I, but none resulted in implant failure. Conclusions Anterior PMMA augmentation during instrumented ALIF in patients with osteoporosis was useful to prevent cage subsidence and vertebral body collapse. In addition, PMMA augmentation did not increase the nonunion rate and incidence of ASD.

Sign in / Sign up

Export Citation Format

Share Document